DRUG · Unmapped registry intervention
Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
Find medicine records ·
Find other trials using this name
Clinical trial
Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC
NCT03428022
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedApatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Shenzhen People's Hospitallead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03428022 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.